Synergy Pharmaceuticals Appears To Be Back On Track At Last
Synergy has faced the daunting task of commercializing constipation drug Trulance via a risky go-it-alone strategy; initial efforts were ruinously expensive and yielded anemic prescription growth.
The company reported Q2 earnings on Aug. 7; it showed major growth in net sales while also reducing operating expenses considerably.
Synergy has been further bolstered by strategic wins, including an out-license partnership to reach the Chinese market and the addition of Trulance to Express Scripts’ preferred formulary for 2019.
The market has not yet forgiven Synergy for its botched initial commercialization effort and subsequent dilutive stock offering.
With solid sales growth and costs under control, Synergy may approach profitability by the second half of 2019; that makes the current share price look very cheap.
https://seekingalpha.com/article/4200436-synergy-pharmaceuticals-appears-back-track-last